Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSE - Gemcitabine + cisplatin + sorafenib vs placebo in advanced urothelial carcinoma
DRKS00003397Phase 2Terminated
- Sponsor
- Universitätsmedizin Essen
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in transitional cell carcinoma (TCC), bladder cancer, sponsored by Universitätsmedizin Essen. Started Jan 2012; status: terminated.
02
Drugs
sorafenib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on DRKS00003397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003397.